Gilead Sciences (NASDAQ:GILD - Get Free Report) had its target price upped by research analysts at Wolfe Research from $135.00 to $140.00 in a report released on Thursday,MarketScreener reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. Wolfe Research's price objective indicates a potential upside of 15.41% from the stock's previous close.
GILD has been the subject of a number of other research reports. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an "overweight" rating in a research note on Thursday, October 9th. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a "neutral" rating in a research note on Friday, October 17th. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "outperform" rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $122.61.
Get Our Latest Analysis on Gilead Sciences
Gilead Sciences Price Performance
NASDAQ:GILD opened at $121.30 on Thursday. The stock has a 50 day moving average of $115.38 and a two-hundred day moving average of $110.78. Gilead Sciences has a 12 month low of $86.08 and a 12 month high of $124.61. The firm has a market cap of $150.51 billion, a P/E ratio of 24.19, a price-to-earnings-growth ratio of 0.85 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The business's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. One Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock worth $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC raised its stake in Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after buying an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 109 shares during the last quarter. Covea Finance lifted its holdings in Gilead Sciences by 69.5% during the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock worth $5,732,000 after buying an additional 21,200 shares during the last quarter. Finally, Swedbank AB boosted its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after acquiring an additional 16,663 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
